---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-285325"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:51:50.095707+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics doses first patient in Phase 1 trial of HCW9302 for alopecia areata

## Summary
- First patient dosed at Ohio State University Wexner Medical Center in multi-center first-in-human Phase 1 trial.
- HCW9302 is a subcutaneous IL-2 fusion molecule designed to expand Treg cells, built on the TOBI platform.
- Trial plans to enroll up to 30 patients; primary objectives are safety and determination of recommended Phase 2 dose.
- Secondary endpoints include disease response and effects on Treg cell proliferation; expansion into other autoimmune and inflammatory conditions is planned.

## SEC filing metadata
- accession: 0001193125-25-285325
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000119312525285325/0001193125-25-285325-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000119312525285325/hcwb-20251117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-285325
- JSON: https://secwatch.observer/filing/0001193125-25-285325.json
- Plain text: https://secwatch.observer/filing/0001193125-25-285325.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.